Systems biology and theranostic approach to drug discovery and development to treat traumatic brain injury.
Traumatic brain injury is a significant disease affecting 1.4 to 2 million patients every year in the USA. Currently, there are no FDA-approved therapeutic remedies to treat TBI despite the fact that there have been over 200 clinical drug trials, all which have failed. These drugs used the traditional single drug-to-target approach of drug discovery and development. An alternative based upon the advances in genomics, proteomics, bioinformatic tools, and systems biology software has enabled us to use a Systems Biology-based approach to drug discovery and development for TBI. It focuses on disease-relevant converging pathways as potential therapeutic intervention points and is accompanied by downstream biomarkers that allow for the tracking of drug targeting and appears to correlate with disease mitigation. When realized, one is able to envision that a companion diagnostic will be codeveloped along the therapeutic compound. This "theranostic" approach is perfectly positioned to align with the emerging trend toward "personalized medicine".
Zhang
Zhiqun
Z
Center of Innovative Research, Banyan Biomarkers, Inc., Alachua, FL, USA.
Larner
Stephen F
SF
Kobeissy
Firas
F
Hayes
Ronald L
RL
Wang
Kevin K W
KK
D000328:Adult; D000818:Animals; D001930:Brain Injuries / Q000175:diagnosis* / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D002986:Clinical Trials as Topic; D017277:Drug Approval; D055808:Drug Discovery / Q000379:methods*; D004353:Drug Evaluation, Preclinical; D006801:Humans; D011358:Product Surveillance, Postmarketing; D049490:Systems Biology / Q000379:methods*; D057170:Translational Research, Biomedical; D014481:United States; D014486:United States Food and Drug Administration